C. Difficile Toxoid Vaccine for Sustained Neutralizing Immunity

The patent applies this principle by chemically modifying the C. difficile toxins (TcdA and TcdB) to create toxoids that retain immunogenicity while eliminating toxicity. The toxins are treated with formaldehyde or glutaraldehyde to crosslink amino groups, converting the harmful toxic proteins into beneficial vaccine antigens that stimulate protective immunity without causing disease.

The patent changes the chemical parameters of the toxin molecules by introducing crosslinks between amino groups using formaldehyde or glutaraldehyde. This chemical modification alters the conformational flexibility and stability of the toxins, reducing their toxic activity while preserving their ability to elicit an immune response. The degree of crosslinking is controlled to optimize the balance between immunogenicity and safety.

The patent develops toxoid vaccines that can protect against multiple C. difficile strains and toxin variants. By selecting toxin sequences that represent conserved regions across different strains and applying uniform chemical modification protocols, the vaccine achieves broad-spectrum protection. This multi-functional approach allows a single vaccine formulation to address diverse CDIs without requiring separate vaccines for each strain.

The patent addresses toxin diversity by selecting specific epitopic regions from toxin sequences that are conserved across multiple strains. Rather than including all possible toxin variants, the vaccine focuses on key immunogenic segments that elicit cross-protective immunity. This segmentation strategy simplifies manufacturing while maintaining broad coverage.